微血管不稳定标志物可预测特发性肺纤维化的严重程度与生存
研究基于肺纤维化基金会患者登记库(n=914)及独立验证队列(n=366),筛选79种微血管相关蛋白,构建微血管风险评分。五种血浆蛋白(SDC1、MMP10、THBS2、HGF、SERPINA5)升高与肺功能及生存相关;高微血管风险患者后续接受尼达尼布治疗者3年无移植生存显著优于未接受抗纤维化干预者(HR 0.56,95%CI 0.35-0.89,p=0.0142)。
要点
- 五种微血管相关血浆蛋白与IPF肺功能及生存相关
- 高微血管风险患者接受尼达尼布3年无移植生存更优
- 微血管重塑紊乱参与IPF疾病严重程度与进展
核心结论
- 多组学分析提示微血管重塑异常参与IPF疾病严重程度与进展。
- 该分析为IPF精准医学方法提供了框架。
研究设计与样本
- 从肺纤维化基金会患者登记库(PFF-PR)获取IPF患者Olink蛋白组学数据(n=914)。
- 独立验证队列n=366。
- PFF-PR中640例患者另有全血RNA测序数据。
- 筛选79种微血管相关蛋白,分析其与疾病严重程度及无移植生存的关联。
- 采用自适应LASSO构建微血管风险评分。
主要发现
- 五种微血管相关蛋白(SDC1、MMP10、THBS2、HGF、SERPINA5)血浆水平较高与两个队列中肺功能及生存相关。
- 高微血管风险患者全血RNA测序显示免疫介导过程富集。
- 高微血管风险患者后续一年内接受尼达尼布者3年无移植生存显著优于未接受抗纤维化干预者(HR 0.56,95%CI 0.35-0.89,p=0.0142)。
关键数值与推荐
- 五种微血管相关蛋白:SDC1、MMP10、THBS2、HGF、SERPINA5。
- 高微血管风险后接受尼达尼布 vs 未接受抗纤维化干预:3年无移植生存HR 0.56(95%CI 0.35-0.89),p=0.0142。
临床怎么用
- 微血管相关蛋白标志物或可用于IPF风险分层与严重程度评估。
- 高微血管风险患者接受尼达尼布可能改善无移植生存。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Most research on idiopathic pulmonary fibrosis (IPF) has focused on the interplay among fibroblasts, the immune system and epithelial cells. There is growing evidence that microvascular dysfunction also plays a role in disease progression, but large human translational studies are lacking. In this research, we aim to identify a proteomic signature of microvascular instability and assess the impact of current therapeutics on the microvasculature. METHODS: Olink proteomic data from patients with IPF were obtained from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR) (n=914) and an independent validation cohort (n=366). Among the PFF-PR, 640 patients also have whole-blood RNA sequencing data available. A subset of 79 microvascular-associated proteins was curated, and their associations with disease severity and transplant-free survival were examined. An adaptive least absolute shrinkage and selection operator was used to generate a novel microvascular risk score. RESULTS: Higher plasma levels of five microvascular-associated proteins (SDC1, MMP10, THBS2, HGF and SERPINA5) were associated with lung function and survival in both cohorts. Whole-blood RNA sequencing of patients with microvascular risk revealed enrichment of immune-mediated processes. Patients with higher microvascular risk who were subsequently put on nintedanib in the following year had significantly better 3-year transplant-free survival compared with patients who did not receive antifibrotic intervention (HR 0.56, 95% CI 0.35 to 0.89, p=0.0142). DISCUSSION: Integrative multi-omics analyses suggest that perturbations to microvascular remodelling contribute to disease severity and progression in IPF. This analysis offers a framework for a precision medicine approach for IPF.
引用
- Csordas DJ, Ma SF, Huang Y, et al. Markers of microvascular instability predict severity and survival in idiopathic pulmonary fibrosis. Thorax. 2026. PMID: 42722423. doi:10.1136/thorax-2026-225147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。